No Prescription |
 |
 | ||
|
Singulair Generic Montelukast sodium |
|
| ||
No Prescription » Prescription Drugs 15 » Singulair Generic Montelukast sodium Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:Maintenance treatment in asthma. Prevention and long-term treatment of asthma. It is also used to relieve allergy symptoms SINGULAIR is used to prevent asthma symptoms including those that occur during the day and at night-time. It also prevents the narrowing of airways triggered by exercise. Singulair is used for long-term prevention of asthma. It reduces the swelling and inflammation that tend to close up the airways and relaxes the walls of the bronchial tubes expanding the airways and permitting more air to pass through. Montelukast (mon-te-LOO-kast) is used in mild to moderate asthma to decrease the symptoms of asthma and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started. This medicine is also used to treat the symptoms (sneezing runny nose itching wheezing) of seasonal (short-term) allergies. Buy Singulair Generic Montelukast sodium and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Singulair Generic Montelukast sodium: Product Type: Prescription Drugs 15 Singulair ( Generic Montelukast sodium ) Singulair (Generic Montelukast sodium) Generic Montelukast sodium 10mg Generic Montelukast sodium Singulair
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
